I reckon something will give in the next 6/12 months!Kind regards, GHFrivaldo: I for one will be extremely happy for the directors if the share price exceeds the 45p required for full vesting: "The options vest in three equal instalments when the Company's share price trades at 25p, 35p and 45p for twenty consecutive days." Most options are exercisable either at the current share price or, in some cases, with no exercise price at all - pure profit.
Their forecasts are: this year : €1.83 EPS, €3.62m cash pile next year : €2.07 EPS, €4.03m cash pile "Solid H1 2017 After a lacklustre full year results released in March 2017, the growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceuticals, biotechnology and medical device clients today provided a trading update for the six months ended 30 June 2017.
The new financial year started well with the Company securing contract wins in January and February with a value of €5.7m.
Venn Life Sciences Daily Update: Venn Life Sciences Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker VENN.
The last closing price for Venn Life Sciences was 6.85p.
Businesses are clearly not falling over each other to use Venn.
Regardless of 'delay' talk, revenue has been gradually dropping for some years.yump: Nothing in the statement, so share price does nothing. The absence of negatives (possible revenue hit) is I suppose a positive and may mean that they would actually have posted a revenue gain, if the delayed work hadn't been put back to Q1 2018.
As you've pointed out, VENN are forecast to deliver €18.5m turnover this year & had turnover of €18m last year which is a respectable size business that a bidder may see as an opportunity to build economies of scale with an existing business, or perhaps build a business around it in terms of Private Equity initiating a buy/build model.
VENN's share price is down 50% in the last 12 months & market cap £7.6m with EV of £5.0m.
We estimate that the Sedana contract announced in November 2016 and the €5.7m contracts won in January and February this year will contribute €4.3m in fee income in the current year.
The Company has a strong proposal book, which should begin to turn in to business wins now that the full R&D lifecycle proposition is up and running.
They're paying €5.7m for a business with €4.7m of annual revenues and €0.34m EBITDA.